Cencora, Inc. · NYSE:COR
Cencora — AmerisourceBergen — Q1 2022 Earnings Presentation
14 slides from Cencora's earnings presentation, Feb 2, 2022
Slide 1: Q1 FY2022 Financial Results
Q1 FY2022 Financial Results February 2, 2022
Slide 2: Cautionary note regarding forward-looking statements
Cautionary note regarding forward-looking statements Certain of the statements contained in this presentation are "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended (the "Securit
Slide 3: United in our responsibility to create healthier futures
AmerisourceBergen is united in our responsibility to create healthier futures. AmerisourceBergen creates unparalleled access, efficiency, and reliability for human and animal health as a leading provider of pharmaceutical distribution services and differentiated value-added solutions for upstream an
Slide 4: Overview
Overview Recent highlights Global healthcare Fiscal 2022 guidance leader • Growth driven by solid • Foundation of leadership • Updated fiscal 2022 underlying business in pharmaceutical guidance reflects updated fundamentals and distribution full year expectations from contribution from • Complementa
Slide 5: Q1 FY2022 financial results
Q1 FY2022 financial results Consolidated results GAAP Adjusted (non-GAAP)1 Revenue $59.6B $59.6B % Change (Year-over-Year) 13.5% 13.5% Gross profit $2.1B $2.0B % Change 41.9% 41.3% Operating expenses $1.4B $1.3B % Change 56.5% 56.4% Operating income $644M $749M % Change 17.8% 21.4% Interest expense,
Slide 6: U.S. Healthcare Solutions segment
Q1 FY2022 financial results U.S. Healthcare Solutions segment Q1 FY2022 Q1 FY2021 YoY Change Revenue $53.0B $51.6B 2.7% Operating income $569M $566M 0.6% Percentages of revenue Gross profit 2.41% 2.41% Operating expenses 1.34% 1.31% Operating income 1.07% 1.10% ▪ U.S. Healthcare Solutions consists o
Slide 7: International Healthcare Solutions segment
Q1 FY2022 financial results International Healthcare Solutions segment Q1 FY2022 Q1 FY2021 YoY Change Revenue, as reported $6.6B $944M 604.2% Revenue, constant currency $6.9B 632% Operating income, as reported $180M $51M 253.1% Operating Income, constant currency $187M 268% Percentages of revenue, a
Slide 8: FY2022 guidance
FY2022 guidance Updated guidance reflects full year expectations for COVID therapy distribution and higher interest expense Revenue High-single to low-double digit percent growth U.S. Healthcare Solutions revenue $207 billion to $212 billion represents growth of 2% to 5% International Healthcare Sol
Slide 9: Creating differentiated value for our stakeholders
Creating differentiated value for our stakeholders Our long-term, sustainable growth is supported by investments in our people and culture and commitment to ESG Why we exist We are united in our responsibility to create healthier futures Our areas of focus Specialty medicine Community providers Cust
Slide 10: Advancing environmental, social, and governance initiatives
Advancing environmental, social, and governance initiatives to create healthier futures around the world ENVIRONMENTAL SOCIAL Adapting to a changing climate Investing in our people and communities • Reduced greenhouse gas emissions by 10.5% • Long-term diversity, equity, and inclusion in fiscal 2020
Slide 11: Appendix
Appendix
Slide 12: Note: For more information related to non-GAAP financial measures, refer to the section titled
1. Includes a $5.3 million gain on the currency remeasurement of the deferred tax assets relating to Swiss tax reform, which is recorded within Other Income, Net. 12 Note: For more information related to non-GAAP financial measures, refer to the section titled “Supplemental Information Regarding Non
Slide 13: Note: For more information related to non-GAAP financial measures, refer to the section titled
1. Represents discrete tax benefits primarily attributable to the income tax deductions resulting from the permanent shutdown of the PharMEDium business. 2. Represents tax expense relating to Swiss tax reform and a $14.0 million gain on the currency remeasurement of the related deferred tax assets,
Slide 14: Contact
Contact Bennett S. Murphy Senior Vice President Investor Relations bmurphy@amerisourcebergen.com